Avidity Biosciences Inc (RNAM) Stock Analysis

What Avidity Biosciences Inc does

Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.

Key metrics

ETFs linked to RNAM

Broad-market and Healthcare sector ETFs an investor holding Avidity Biosciences Inc is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how RNAM fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Avidity Biosciences Inc?

Avidity Biosciences Inc trades under the ticker RNAM on NASDAQ.

Which exchange is RNAM listed on?

RNAM is listed on NASDAQ.

What sector does Avidity Biosciences Inc operate in?

Avidity Biosciences Inc is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze RNAM in a portfolio?

PortView shows RNAM's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.